Background/Objectives: Dysregulation of purinergic signaling, particularly CD73 overexpression, influences tumor progression, immune evasion, and chemoresistance in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from The Cancer Genome Atlas—Liver Hepatocellular Carcinoma (TCGA-LIHC) to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation. Specifically, analysis of the TCGA cohort indicated that high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. Given the critical role of CD73 in therapy resistance, we evaluated these findings in 3D models. Co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For the ADA, effect-size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed that high CD73 protein expression remained stable across treatments in co-culture, the combination therapy overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared with vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine pathway and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.
Background: Hepatic stellate cells (HSCs) are major regulators of the hepatocellular carcinoma (HCC) tumor microenvironment, contributing to extracellular matrix remodeling, tumor progression, and therapeutic resistance. Although three-dimensional (3D) coculture spheroid models better represent tumor-stroma interactions than conventional monocultures, the impact of HSCs on spheroid architecture and function remains incompletely characterized. This study investigated how HSCs influence the structural and functional properties of a 3D HCC model. Methods and results: Spheroids were produced using HepG2 cells, LX-2 cells (HSCs), or a 1:1 coculture system (CCS) and characterized over 96 h. Morphometric analysis demonstrated that CCS spheroids exhibited reduced area and perimeter together with increased circularity and normalized solidity, indicating enhanced structural organization and compaction. Scanning electron microscopy (SEM) confirmed distinct ultrastructural organization among the spheroid models. Flow cytometry revealed fewer membrane-compromised cells in CCS spheroids than in HepG2 spheroids. Although the percentage of active caspase−3-positive cells was unchanged, active caspase−3 fluorescence intensity was lower in both HepG2-like and LX-2-like populations. CCS spheroids showed higher collagen type I alpha-1-associated fluorescence, predominantly in the α-SMA-positive compartment, consistent with a stromal collagen-producing phenotype. Biochemical analyses revealed distinct extracellular lactate profiles. Extracellular LDH activity was lower in CCS spheroids than in HepG2 spheroids, although normalized LDH release did not differ between these groups. Functionally, CCS spheroids displayed reduced sorafenib sensitivity, with an IC30 approximately 3-fold higher than HepG2 monoculture. Conclusions: LX-2 incorporation was associated with greater spheroid organization, increased collagen type I-related expression, altered cell-death and extracellular metabolic profiles, and reduced sorafenib sensitivity, supporting the value of HepG2/LX-2 coculture spheroids for studying selected tumor–stromal interactions.
Background/Objectives: Dysregulation of purinergic signaling influences tumor progression and immune evasion in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from the TCGA-LIHC to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation, where high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. In 3D models, co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For ADA, effect size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed high CD73 protein expression remained stable across treatments in co-culture, the combination therapy successfully overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared to vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine-generating axis and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.